US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi U.S. Biotech 2x Daily ETF

36.28

+1.855.36%

Pre-market: 37.391.11+3.05%07:21 EDT

Volume:90

Turnover:3K

Market Cap:544.23K

PE:- -

High:36.28

Open:34.44

Low:36.28

Close:34.44

52wk High:42.22

52wk Low:25.26

Shares:15.00K

Float Shares:15.00K

Volume Ratio:1.34

T/O Rate:0.60%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing

Syngenis banks R&D refund to fuel biotech build-out

The West Australian

Moderna’s Shock Rally Redraws the Biotech Playbook

VOOLT boosts deeptech portfolio with stake in cancer-vaccine biotech Vaxican

Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast

Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live

Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

From petri dish to patient:biotech’s formidable obstacle course

The West Australian

NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy

Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial

Grail announces FDA advisory committee meeting to review Galleri test PMA

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

MT Newswires Live

AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape

Recce Pharmaceuticals Seeks ASX Quotation for Advisory Fee Shares

Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances

PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year

Kazia Therapeutics Files Provisional Patent Backing New Paxalisib Strategy in High-Risk Early TNBC

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/XBIX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"XBIX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBIX\",,,,,undefined,":{"symbol":"XBIX","market":"US","secType":"STK","nameCN":"Corgi U.S. Biotech 2x Daily ETF","latestPrice":36.282,"timestamp":1789675200000,"preClose":34.4365,"halted":0,"volume":90,"hourTrading":{"tag":"盘前","latestPrice":37.39,"preClose":36.282,"latestTime":"07:21 EDT","volume":2,"amount":74.78,"timestamp":1789730471614,"change":1.108,"changeRate":0.030539,"amplitude":0},"delay":0,"changeRate":0.05359139285351281,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"Pre-Mkt","change":1.8455,"latestTime":"09-18 08:52:04 EDT","open":34.4365,"high":36.282,"low":36.282,"amount":3323,"amplitude":0,"askPrice":58.05,"askSize":200,"bidPrice":19.21,"bidSize":100,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"exchange":"CBOE","adjPreClose":36.282,"nav":34.44,"aum":516600,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":37.39,"preClose":36.282,"latestTime":"07:21 EDT","volume":2,"amount":74.78,"timestamp":1789730471614,"change":1.108,"changeRate":0.030539,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":34.4365,"preClose":36.282,"latestTime":"16:10 EDT","volume":2,"amount":72.564,"timestamp":1789675804544,"change":-1.8455,"changeRate":-0.050865,"amplitude":0},"volumeRatio":1.3353078084794718},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBIX\",,,,,undefined,":{"symbol":"XBIX","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.3353078084794718,"shares":15000,"dividePrice":0,"high":36.282,"amplitude":0,"preClose":34.4365,"low":36.282,"week52Low":25.2639,"pbRate":"--","week52High":42.2188,"institutionHeld":0,"latestPrice":36.282,"committee":-0.333333,"eps":0,"divideRate":0,"volume":90,"delay":0,"ttmEps":0,"open":34.4365,"prevYearClose":25.42,"prevWeekClose":35.4698,"prevMonthClose":38.5461,"prevQuarterClose":37.7974,"fiveDayClose":35.7203,"twentyDayClose":42.2188,"sixtyDayClose":32.8188},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBIX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBIX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBIX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBIX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662760410","title":"4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760410","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760410?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:13","pubTimestamp":1787724830,"startTime":"0","endTime":"0","summary":"4basebio UK Societas ( ($GB:4BB) ) has issued an update. 4basebio PLC, a UK-listed biotech focused on synthetic, cell-free DNA and mRNA for advance...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNA","BK4121","XBIX","BK4561","VAQC","NVIB","BK4109","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204407","title":"Syngenis banks R&D refund to fuel biotech build-out","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204407","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204407?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:06","pubTimestamp":1787584007,"startTime":"0","endTime":"0","summary":"Biotech hopeful Syngenis Labs has banked a $363,000 R&D tax refund atop a recent $4 million pre-IPO raise, adding non-dilutive firepower as it builds out its Australian RNA and DNA manufacturing platform.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-22771960/cfe32dd8d5c27df108386c3ef5f67af0dd0eab91.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22771960/cfe32dd8d5c27df108386c3ef5f67af0dd0eab91.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/syngenis-banks-rd-refund-to-fuel-biotech-build-out-c-22771960","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/syngenis-banks-rd-refund-to-fuel-biotech-build-out-c-22771960","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["GLP","XBIX","BK4590","NVIB","BK4144","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219445","title":"Moderna’s Shock Rally Redraws the Biotech Playbook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661219445?lang=en_us&edition=fundamental","pubTime":"2026-08-22 22:01","pubTimestamp":1787407292,"startTime":"0","endTime":"0","summary":"Moderna ( ($MRNA) ) has risen by 125.15%. Read on to learn why. Moderna has delivered one of the most dramatic moves in biotech this week, with its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/modernas-shock-rally-redraws-the-biotech-playbook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/modernas-shock-rally-redraws-the-biotech-playbook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","XBI","WDNA","MRNX","GNOM","MRNA","BK4548","BK4551","LGHT","BK4588","IDNA","NVIB","BK4585","MRNY","BK4581","BK4533","BK4501","XBIX","BK4568","BK4534","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660845542","title":"VOOLT boosts deeptech portfolio with stake in cancer-vaccine biotech Vaxican","url":"https://stock-news.laohu8.com/highlight/detail?id=2660845542","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660845542?lang=en_us&edition=fundamental","pubTime":"2026-08-20 20:17","pubTimestamp":1787228270,"startTime":"0","endTime":"0","summary":"The latest update is out from VOOLT Spolka Akcyjna ( ($PL:VLT) ). VOOLT S.A. has signed a preliminary agreement to acquire 108 shares in Polish bio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-stake-in-cancer-vaccine-biotech-vaxican?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-boosts-deeptech-portfolio-with-stake-in-cancer-vaccine-biotech-vaxican?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB","VLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660835402","title":"Arctic Bioscience Sets Date for H1 2026 Results and Investor Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2660835402","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660835402?lang=en_us&edition=fundamental","pubTime":"2026-08-20 16:08","pubTimestamp":1787213283,"startTime":"0","endTime":"0","summary":"An announcement from Arctic Bioscience AS ( ($DE:9TD) ) is now available. Arctic Bioscience AS, a biotech company specializing in pharmaceutical an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/arctic-bioscience-sets-date-for-h1-2026-results-and-investor-webcast?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LNGR","XBIX","NVIB","AS","BK4202","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479252","title":"Memphasys Secures Vietnam Registration for Felix System, Triggers First Major Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479252","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479252?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:31","pubTimestamp":1787182297,"startTime":"0","endTime":"0","summary":"Memphasys Ltd ( ($AU:MEM) ) has shared an announcement. Memphasys Ltd, an Australian reproductive biotech specialist, is commercialising its Felix ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/memphasys-secures-vietnam-registration-for-felix-system-triggers-first-major-order?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/memphasys-secures-vietnam-registration-for-felix-system-triggers-first-major-order?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","MEM","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421716","title":"European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421716","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421716?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:18","pubTimestamp":1787152727,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.68% to 1,973.64 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm BioNTech  and biopharmaceutical company Grifols , which advanced 24% and 5.6% respectively. They were followed by semiconductor company Sequans Communications  and biopharmaceutical company argenx , which rose 3.3% and 3% respectively.The decliners from continental Europe were led by internet browser company Opera  and biotech firm Evaxion , which fell 7.9% and 6% respectively. They were followed by accommodations booking site Trivago  and telecommunications company Nokia , which were down 4.3% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics  and mining company BHP Group , which increased 9.2% and 4.5% respectively. They were followed by software firm Endava  and biopharmaceutical company Bicycle Therapeutics , w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVIB","IE00BJJMRZ35.SGD","IE0009355771.USD","LNOK","BK4547","BK4585","OPRA","SNN","LU0109394709.USD","SLX","LU0823416689.USD","TRVG","LU0300736062.USD","AFG","FMED","GRFS","IBB","IE00B4R5TH58.HKD","BK4548","IE00BMPRXN33.USD","IEUR","IE00B2B36J28.USD","ARGX","IE00BJT1NW94.SGD","TRIB","LFGY","LU1983260115.SGD","BK4117","TBXU","NOK","DAVA.AU","LU0648005311.SGD","BHP.AU","COAL","LU0006061336.USD","EPV","BDRX","LU0889565916.HKD","PUK","BNTX","SQNS","AUTL","EVAX","DAVA","BK4141","BK4588","XBIX","LU2324357040.USD","BCYC","BHP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499847","title":"Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499847","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660499847?lang=en_us&edition=fundamental","pubTime":"2026-08-19 01:02","pubTimestamp":1787072575,"startTime":"0","endTime":"0","summary":"Vivoryon Therapeutics AG ( ($NL:VVY) ) has issued an announcement. Vivoryon Therapeutics N.V., a Germany-based clinical-stage biotech listed on Eur...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivoryon-sets-date-for-2026-agm-as-kidney-disease-program-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","BK4229","NVIB","AGM","BBC","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","BK1583","LU0611395673.USD","LU0700851271.USD","LU1719994722.HKD","BBC","PSIL","LU1979443071.USD","BK1141","LU1303224171.USD","APXH","LFSC","LU1997244956.HKD","LU1770034418.SGD","MEDI","LU0708995583.HKD","LU0348766576.USD","IDNA","BK1576","LU2488822045.USD","LU2125910500.SGD","LU0348767384.USD","LU2328871848.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1046422090.SGD","161027","BMED","LU0320764599.SGD","LU1997245094.SGD","LU1997245177.USD","XBIX","SMCO","IBRN","LU1969619763.USD","CXO","FHLC","LU2495084118.USD","02359","IE00BPRC5H50.USD","LU1251922891.USD","603259","WX","LU0456842615.SGD","LU2045819591.USD","SURI","LU1808992512.USD","LU2242644610.SGD","BK0216","PSCH","LU1934453819.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","APXH","LU1880383366.USD","LU1720050803.USD","PSCH","LU0039217434.USD","LU0359201612.USD","LU1046422090.SGD","LU0348766576.USD","WX","LU0052750758.USD","LU0516423174.USD","LU0823426480.USD","LU0359202008.SGD","LU1997245094.SGD","BK0216","LU1719994722.HKD","LU0611395673.USD","LU1997245177.USD","BK1610","LU1808992512.USD","02269","603259","LU0516423091.SGD","XBIX","BBC","LU1242518857.USD","LU0320764599.SGD","LU0588546209.SGD","LU2125910500.SGD","LU0348735423.USD","IE00BPRC5H50.USD","IE00B0JY6N72.USD","BK1583","IE00B543WZ88.USD","LU0140636845.USD","PSIL","IE00B5MMRT66.SGD","LU2039709279.SGD","SG9999002463.SGD","LU2495084118.USD","BK1521","LU0700851271.USD","LU0456842615.SGD","LU1251922891.USD","BK1576","LU0417516902.SGD","LU0456846285.SGD","LU2488822045.USD","LFSC","LU3063872942.SGD","BMED","LU1770034418.SGD","LU0307460666.USD","LU1303224171.USD","LU0327786744.USD","LU0051755006.USD","LU1794554557.SGD","IDNA","BK1589","LU0417516738.SGD","LU0326950275.SGD","LU0181495838.USD","LU0708995583.HKD","LU0856984785.SGD","LU1688375341.USD","LU0456827905.SGD","LU0128526141.USD","LU0029874061.USD","LU2045819591.USD","FHLC","LU1979443071.USD","161027","LU0348825331.USD","LU1997244956.HKD","SURI","LU1969619763.USD","LU1242518931.SGD","MEDI","LU0572944931.SGD","KURE","CXO","LU0823426308.USD","LU0516422440.USD","SG9999002562.SGD","LU0043850808.USD","LU2242644610.SGD","LU1934453819.USD","SMCO","LU0516422366.SGD","LU0348767384.USD","02359","LU2328871848.SGD","LU0516422952.EUR","03759","LU0819121731.USD","IBRN","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131647","title":"From petri dish to patient:biotech’s formidable obstacle course","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131647","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659131647?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:12","pubTimestamp":1786576331,"startTime":"0","endTime":"0","summary":"A biotech breakthrough can be worth billions – if it survives the journey. Bulls N’ Bears follows the trek from a promising discovery through to a product doctors can actually use.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22720423/37f3ab3f7c773a9a699efc346c96f6d2e782abe6.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22720423/37f3ab3f7c773a9a699efc346c96f6d2e782abe6.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/from-petri-dish-to-patientbiotechs-formidable-obstacle-course-c-22720423","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/from-petri-dish-to-patientbiotechs-formidable-obstacle-course-c-22720423","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["XBIX","EES","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658700929","title":"NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658700929","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658700929?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:08","pubTimestamp":1786540125,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs Inc., a clinical-stage biotech and majority-owned subsidiary of SciSparc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930455","title":"Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930455","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658930455?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:55","pubTimestamp":1786377312,"startTime":"0","endTime":"0","summary":"Shares of American biotech company Vertex Pharmaceuticals ($VRTX) jumped about 7% on Monday after its top rival Sionna Therapeutics ($SION) reporte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/vertex-stock-vrtx-soars-7-as-rival-sionna-sion-crashes-92-on-failed-drug-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/vertex-stock-vrtx-soars-7-as-rival-sionna-sion-crashes-92-on-failed-drug-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2417539215.USD","LU0417517546.SGD","LU2362540622.SGD","LU0823416689.USD","LU0079474960.USD","IE00B19Z3B42.SGD","IE00B2B36J28.USD","LU2237438978.USD","LU0058720904.USD","SION","BBH","LU2362541513.USD","LU1674673428.USD","LU0757428866.USD","LU2468319806.SGD","BK4533","IE00B19Z9P08.USD","BIB","IE00BFTCPJ56.SGD","GNMX","LU0061475181.USD","BK4139","BK4532","LU0566484027.USD","LU0432979614.USD","LU1093756325.SGD","IE00BJT1NW94.SGD","VERX","IDNA","LU2362541273.HKD","BK4588","IE00B4R5TH58.HKD","VRTX","LU1815336091.USD","LU2324357040.USD","PBE","TBXU","IE00B19Z9Z06.USD","LU2456880835.USD","LU1430594728.SGD","IBBQ","SGXZ57979304.SGD","IBB","LU1035775433.USD","IE0002141913.USD","LU2462157665.USD","XBIX","LU0889565916.HKD","BK4585","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657642727","title":"Grail announces FDA advisory committee meeting to review Galleri test PMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2657642727","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657642727?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:10","pubTimestamp":1786115445,"startTime":"0","endTime":"0","summary":"GRAIL (GRAL) announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/grail-announces-fda-advisory-committee-meeting-to-review-galleri-test-pma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/grail-announces-fda-advisory-committee-meeting-to-review-galleri-test-pma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4129","BK4588","PMA","BK4585","LABU","IBRN","BK4139","BBH","BBP","GRAL","PBE","SBIO","FBT","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653126","title":"European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653126","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653126?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:18","pubTimestamp":1786029491,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were heading higher late Thursday morning, rising 0.85% to 1,947.79 on the S&P Europe Select ADR Index.From continental Europe, the g","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","CRTO","BK4023","EVAX","NVIB","BK4588","IE00BFMHRM44.USD","BK4169","BK4107","AFG","BK4139","ASND","BK4548","BDRX","BBVA","BK4585","DGE.UK","LU0320765992.SGD","MREO","TRVG","IEUR","BK4111","BK4009","OPRA","BNTX","BK4082","TRIB","BK4207","EPV","AUTL","BK4204","WPP.AU","CLLS","WPP","BK4117","BK4077","MEDI","LU0109394709.USD","LFGY","BK4559","BK4535","SNN","XBIX","BK4551","BK4568","DEO","PSO","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167771958","title":"AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=1167771958","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167771958?lang=en_us&edition=fundamental","pubTime":"2026-08-03 07:33","pubTimestamp":1785713585,"startTime":"0","endTime":"0","summary":"AstraZeneca PLC (AZN.US) has been in early-stage discussions about acquiring Bristol-Myers Squibb (BMY.US), a move that could create one of the world's largest pharmaceutical companies, according to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"AstraZeneca Explores Blockbuster Bristol-Myers Squibb Deal Reshaping Global Pharma Landscape","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","BK4581","PPH","LU1868837300.USD","LU2473716301.USD","IE00BSNM7G36.USD","LU0432979614.USD","IE00BFXG1179.USD","LU2596442595.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU1093756168.USD","LU2089984988.USD","LU0889565916.HKD","IE0009355771.USD","FXH","LU2125154778.USD","LU1868836914.USD","LU1670711040.USD","LU2272731865.HKD","LU1992135399.USD","LU1868836591.USD","LU0267386448.USD","LU2272731600.USD","LU1829250122.USD","LU2322448791.USD","BK4568","LU1989771016.USD","LU0985481810.HKD","LU0306806265.USD","LU0882574055.USD","LU1323610961.USD","LU1868837136.USD","LU1261432733.SGD","LU2456880835.USD","JHMH","LU2237443978.SGD","PILL","BK4534","LU0868494617.USD","LU2322448957.HKD","LU1093756325.SGD","IHE","LU2237443465.HKD","BK4559","LU0109394709.USD","LU1670710588.SGD","LU2417539215.USD","BK4007","LU2237443895.HKD","IE00BFTCPJ56.SGD","AZNH","LU2237443382.USD","LU0310800379.SGD","LU1291159041.SGD","LU1430594728.SGD","LU1983299246.USD","LU2236285917.USD","LU0237698245.USD","IE00B3T34201.USD","LU0225284248.USD","LU2125154935.USD","LU0306807586.USD","LU0096364046.USD","BK4588","LU0708994859.HKD","FHLC","LU2242646821.SGD","LU0321505868.SGD","LU0029864427.USD","MEDI","LU0128525929.USD","LU1032466523.USD","RXD","LU1267930573.SGD","XPH","LU1074936037.SGD","LU0456855351.SGD","IE00BJT1NW94.SGD","LU0061475181.USD","LU2237443549.SGD","LU2468319806.SGD","LU2272731782.SGD","LU1883839398.USD","CURE","IE00BJJMRZ35.SGD","LU0225771236.USD","FTXH","BK4532","LU1670710661.SGD","LU1718418525.SGD","LU1670711123.USD","LU2360032135.SGD","LU0114720955.EUR","RXL","LU2462157665.USD","LU1571399168.USD","SYNB","LU1585245621.USD","LU1992135472.HKD","LU0321505439.SGD","LU2237443622.USD","IEHS","AZN","XBIX","LU1868836757.USD","LU0058720904.USD","LU2242652126.USD","LU0289739699.SGD","LU2133065610.SGD","BK4585","IE0002141913.USD","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656457133","title":"Recce Pharmaceuticals Seeks ASX Quotation for Advisory Fee Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2656457133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656457133?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:42","pubTimestamp":1785710561,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an announcement. Recce Pharmaceuticals Ltd., an Australian biotech company listed on the ASX...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recce-pharmaceuticals-seeks-asx-quotation-for-advisory-fee-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recce-pharmaceuticals-seeks-asx-quotation-for-advisory-fee-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655035713","title":"Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2655035713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655035713?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:12","pubTimestamp":1785492749,"startTime":"0","endTime":"0","summary":"An update from N4 Pharma ( ($GB:THAT) ) is now available. Thalia Therapeutics plc, an AIM-listed clinical-stage biotech specialising in RNA-based t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-updates-voting-rights-as-rna-therapy-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/thalia-therapeutics-updates-voting-rights-as-rna-therapy-pipeline-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","BK4139","BK4588","RNA","NVIB","BBC","BK4585","BK4505","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655030638","title":"PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2655030638","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655030638?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:00","pubTimestamp":1785420050,"startTime":"0","endTime":"0","summary":"“PharmAla’s (MDXXF) financial position continues to improve compared to 2025, in line with the broader growth of the biotech industry,” said Nick K...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pharmala-reports-q3-revenue-c513000-vs-c135000-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pharmala-reports-q3-revenue-c513000-vs-c135000-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDXXF","NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001714","title":"Kazia Therapeutics Files Provisional Patent Backing New Paxalisib Strategy in High-Risk Early TNBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001714?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:57","pubTimestamp":1785239835,"startTime":"0","endTime":"0","summary":"An update from Kazia Therapeutics ( ($KZIA) ) is now available. Kazia Therapeutics Limited, a Sydney-based oncology biotech listed on Nasdaq, is de...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-files-provisional-patent-backing-new-paxalisib-strategy-in-high-risk-early-tnbc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-files-provisional-patent-backing-new-paxalisib-strategy-in-high-risk-early-tnbc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","XBIX","NVIB","BK4007","NQmain","BK4139","CANC","LCLG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}